Vertex Raises 2026 Revenue Guidance to $13.15B–$13.25B
Q3 revenue rose 12% year over year to $3.44 billion. Vertex raised its 2026 revenue guidance from $13.1 billion–$13.2 billion.
Story updates
09:06:57 PM UTC
SquawkNews
*-- GUIDANCE: (VRTX) Vertex Pharmaceuticals Expects 2026 Revenue Range $13.15B-$13.25B, vs. FactSet Est of $13.26B
09:20:46 PM UTC
SquawkNews
By Katherine HamiltonVertex Pharmaceuticals raised its outlook for both sales and expenses to include growth from its recent acquisition of Crinetics Pharmaceuticals.The Boston drug company said it now expects annual revenue to be $13.15 billion to $13.25 billion, up from its prior guidance of $13…
Q3 revenue rose 12% year over year to $3.44B. Vertex raised 2026 revenue guidance to $13.15B—$13.25B from $13.1B—$13.2B previously.Material DetailsContext by AI AnalystThis is a quarterly update showing continued revenue growth alongside a modest increase to the 2026 outlook, following the Crinetic…